Delcath Systems to Present at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Delcath Systems, Inc. (Nasdaq: DCTH) announced its participation in two key conferences. The BTIG Virtual Biotechnology Conference is set for August 9, 2021, from 10:00-10:25 AM ET, featuring management-led 1x1 investor meetings. The Canaccord Genuity 41st Annual Growth Conference will follow on August 11, 2021, at 10:00 AM ET, with a webcast available at this link. Delcath specializes in treating liver cancers through its proprietary PHP system.

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in two upcoming conferences:

BTIG Virtual Biotechnology Conference

• Date and Time: August 9, 2021: 10:00-10:25 AM ET
• Webcast: BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
• Management will also host 1x1 investor meetings during the conference.
  

Canaccord Genuity 41st Annual Growth Conference

• Date and Time: August 11, 2021: 10:00 a.m. ET
• Webcast: https://wsw.com/webcast/canaccord60/dcth/2427436
• Management will also host 1x1 investor meetings during the conference.
  

To learn more about the events or to schedule a one-on-one meeting with Delcath’s management, please contact your conference representative or james@haydenir.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

What is Delcath Systems' participation in the BTIG Virtual Biotechnology Conference?

Delcath Systems will participate in the BTIG Virtual Biotechnology Conference on August 9, 2021, from 10:00-10:25 AM ET and will host 1x1 investor meetings.

When is the Canaccord Genuity 41st Annual Growth Conference?

The Canaccord Genuity 41st Annual Growth Conference is scheduled for August 11, 2021, at 10:00 AM ET.

What is the focus of Delcath Systems' proprietary PHP system?

Delcath Systems' PHP system focuses on administering high-dose chemotherapy specifically for primary and metastatic liver cancers.

Where can I find the webcast for the Canaccord Genuity conference?

The webcast for the Canaccord Genuity conference can be found at this link.

What is the ticker symbol for Delcath Systems?

The ticker symbol for Delcath Systems is DCTH.